BioCentury
ARTICLE | Company News

Astex Pharmaceuticals, Eisai deal

October 15, 2012 7:00 AM UTC

Astex received a $5 million milestone payment from Eisai triggered by the first commercial sale of cancer drug Dacogen decitabine in the EU. Astex will receive royalties starting at 20%, and up to 30%, on global Dacogen sales and is eligible for up to $12.5 million in milestone payments. Last month, the European Commission approved Dacogen to treat newly diagnosed de novo or secondary acute myelogenous leukemia (AML) in patients 65 years and older (see BioCentury, Oct. 1). ...